- CRS Publications
- News
News
Authors:
Date:
Business Wire: November 1, 2016 – SUNNYVALE, CA, U.S.A. – Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, today announced excellent six-month clinical data for the first 25-patient subset of the DESolve™ Cx Clinical…
Authors:
Date:
PRNewswire: October 31, 2016 – MISSISSAUGA, Ontario, Canada – Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ), a global specialty pharmaceutical company, today announced that its subsidiary, Aralez Pharmaceuticals Trading DAC (Aralez Ireland), has completed its acquisition of the U.S. rights…
Authors:
Date:
Business Wire: October 31, 2016 – JERUSALEM, Israel – Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTP), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, announced that the State Intellectual Property Office of the…
Authors:
Date:
PRNewswire: October 31, 2016 – DURHAM, NC, U.S.A. – Micell Technologies, Inc. (Micell) today announced that it presented five-year clinical safety and efficacy results from the DESSOLVE I and II trials of its MiStent sirolimus eluting absorbable polymer coronary stent system (MiStent® ). MiStent is…
Authors:
Date:
Business Wire: October 28, 2016 – LEXINGTON, MA, U.S.A. – CBSET Inc. announced today that it has appointed Dr. Rami Tzafriri as director of research and innovation. Since 2009, Dr. Tzafriri has held the position of principal scientist at CBSET, where he developed quantitative computational and…
Authors:
Date:
Business Wire: October 26, 2016 – AUSTIN, TX, U.S.A. – Mati Therapeutics, Inc. (“Mati”) announced that it has been granted U.S. patent number 9,445,944 titled “Lacrimal Implants and Related Methods.” The patent, which expires in 2028, claims a method of providing a sustained drug release to an eye…
